单位：[1]Anesthesiology Institute, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属同济医院麻醉科麻醉学研究所科研平台[2]Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院麻醉科[3]Department of Psychiatry, UMKC School of Medicine, 1000 E. 24th Street, Kansas City, MO 64108[4]Dep. Of Psychiatry and Behavioral Science, UT Health McGovern Medical School, Houston, TX, 77054[5]Cancer Center, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China.华中科技大学同济医学院附属同济医院肿瘤科
Cancer-induced bone pain (CIBP) remains a major challenge in patients suffering from bone metastases because of the complex mechanisms and unsatisfactory treatments. Emerging evidence have shown that activation of inflammasomes contribute to the development of inflammatory and neuropathic pain. However, the role of spinal inflammasomes in CIBP remains unclear. In the present study, we explored the specific cellular mechanisms of NLRP3 inflammasome in the process of CIBP in rats. MCC950 is a small molecule inhibitor of the NLRP3 inflammasome that exhibits remarkable activity in inflammatory diseases. Our behavioral results confirmed that both single and persistent treatment with MCC950 markedly attenuated CIBP-related mechanical allodynia. The expression of NLRP3 inflammasome, including NLRP3, ASC, Caspase-1, were significantly increased in a time-dependent manner. Furthermore, spinal IL-1 beta, cleaved by cysteine-aspartic acid protease, was upregulated in this study. Chronic administration with MCC950 restored the protein expression of NLRP3 inflammasome and significantly suppressed the upregulation of IL-1 beta. Spinal NLRP3 inflammasome might be a novel therapeutic target for treatment of CIBP.
基金：
National Natural Science Foundation of P.R. ChinaNational Natural Science Foundation of China (NSFC) [81873732, 81371250, 81571053, 81771196]
第一作者单位：[1]Anesthesiology Institute, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.[2]Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
通讯作者：
推荐引用方式(GB/T 7714)：
Chen Shu-Ping,Zhou Ya-Qun,Wang Xiao -Mei,et al.Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain[J].PHARMACOLOGICAL RESEARCH.2019,147:doi:10.1016/j.phrs.2019.104339.
APA：
Chen, Shu-Ping,Zhou, Ya-Qun,Wang, Xiao -Mei,Sun, Jia,Cao, Fei...&Tian, Yu-Ke.(2019).Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain.PHARMACOLOGICAL RESEARCH,147,
MLA：
Chen, Shu-Ping,et al."Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain".PHARMACOLOGICAL RESEARCH 147.(2019)
医学